KR102616835B1 - 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 - Google Patents

개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 Download PDF

Info

Publication number
KR102616835B1
KR102616835B1 KR1020197019686A KR20197019686A KR102616835B1 KR 102616835 B1 KR102616835 B1 KR 102616835B1 KR 1020197019686 A KR1020197019686 A KR 1020197019686A KR 20197019686 A KR20197019686 A KR 20197019686A KR 102616835 B1 KR102616835 B1 KR 102616835B1
Authority
KR
South Korea
Prior art keywords
ser
ala
gly
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197019686A
Other languages
English (en)
Korean (ko)
Other versions
KR20190091524A (ko
Inventor
스테파니 스탤렌스
소렌 스테펜슨
에리카 모리조
라프 폰새르츠
인그리드 오테배르
안 세르도벨
Original Assignee
아블린쓰 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아블린쓰 엔.브이. filed Critical 아블린쓰 엔.브이.
Priority to KR1020237014486A priority Critical patent/KR20230061582A/ko
Priority to KR1020237043751A priority patent/KR20240001271A/ko
Publication of KR20190091524A publication Critical patent/KR20190091524A/ko
Application granted granted Critical
Publication of KR102616835B1 publication Critical patent/KR102616835B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197019686A 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 Active KR102616835B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020237014486A KR20230061582A (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
KR1020237043751A KR20240001271A (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662430972P 2016-12-07 2016-12-07
US62/430,972 2016-12-07
PCT/EP2017/081818 WO2018104444A1 (en) 2016-12-07 2017-12-07 Improved serum albumin binding immunoglobulin single variable domains

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020237014486A Division KR20230061582A (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
KR1020237043751A Division KR20240001271A (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인

Publications (2)

Publication Number Publication Date
KR20190091524A KR20190091524A (ko) 2019-08-06
KR102616835B1 true KR102616835B1 (ko) 2023-12-22

Family

ID=60990745

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237014486A Ceased KR20230061582A (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
KR1020237043751A Ceased KR20240001271A (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
KR1020197019686A Active KR102616835B1 (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020237014486A Ceased KR20230061582A (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
KR1020237043751A Ceased KR20240001271A (ko) 2016-12-07 2017-12-07 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인

Country Status (12)

Country Link
US (2) US11414480B2 (enExample)
EP (1) EP3551656A1 (enExample)
JP (3) JP7417421B2 (enExample)
KR (3) KR20230061582A (enExample)
CN (2) CN117164710A (enExample)
AU (2) AU2017373746B2 (enExample)
BR (1) BR112019011189A2 (enExample)
CA (1) CA3045726A1 (enExample)
IL (2) IL310340A (enExample)
MX (3) MX2019006574A (enExample)
RU (2) RU2022101604A (enExample)
WO (1) WO2018104444A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JP6258199B2 (ja) * 2011-06-23 2018-01-10 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
WO2018127709A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
KR102653724B1 (ko) * 2017-01-17 2024-04-02 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
CN110191896B (zh) 2017-01-17 2023-09-29 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
AU2018363292A1 (en) 2017-11-13 2020-05-21 Crescendo Biologics Limited Molecules that bind to CD137 and PSMA
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
EP3927740A4 (en) * 2019-02-22 2023-03-01 Anwita Biosciences, Inc. ALBUMIN-BINDING ANTIBODIES AND USE THEREOF
CN113840835B (zh) * 2019-05-15 2024-06-25 克雷森多生物制剂有限公司 结合分子
TW202434620A (zh) * 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN112409480B (zh) * 2019-08-20 2024-08-27 四川科伦博泰生物医药股份有限公司 结合血清白蛋白的蛋白及其用途
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
CA3163877A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnf.alpha. and il-23
AU2020397210A1 (en) 2019-12-06 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting TNFa and OX40L
TW202530257A (zh) 2019-12-09 2025-08-01 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
MX2022012278A (es) 2020-03-30 2022-10-27 Ablynx Nv Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
IL303783A (en) 2020-12-18 2023-08-01 Sanofi Sa Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
US20240092919A1 (en) 2020-12-18 2024-03-21 Ablynx N. V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
PE20240233A1 (es) * 2021-02-02 2024-02-16 Lilly Co Eli Fracciones que prolongan la semivida y metodos de uso de estas
MX2024007564A (es) 2021-12-17 2024-07-04 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tcr\03b1\03b2, cd33 y cd123.
AR129614A1 (es) 2022-06-14 2024-09-11 Ablynx Nv Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t
MA71603A (fr) 2022-07-27 2025-05-30 Ablynx Nv Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
KR20250133750A (ko) 2023-01-09 2025-09-08 오디세이 테라퓨틱스, 인코포레이티드 항-tnfr2 항원-결합 단백질 및 그의 용도
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
AU2024234615A1 (en) 2023-03-14 2025-08-21 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
CN121002685A (zh) 2023-05-12 2025-11-21 株式会社Lg新能源 包括用于固定堆叠件的外部的带的电极组件和包括该电极组件的二次电池
AR132699A1 (es) 2023-05-17 2025-07-23 Odyssey Therapeutics Inc Anticuerpos de dominio único modificados
CN116655805B (zh) * 2023-05-31 2024-03-08 四川大学华西医院 一种靶向her2阳性肿瘤的新型car-t细胞及制备方法和应用
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
AR133055A1 (es) * 2023-06-22 2025-08-20 Ablynx Nv Dominios variables únicos de inmunoglobulina dirigidos a pd-l1
AU2024308381A1 (en) 2023-06-29 2025-11-20 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
AR133903A1 (es) 2023-09-22 2025-11-12 Ablynx Nv Agentes de unión de albúmina bi- y multivalentes
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
TW202530265A (zh) 2023-10-13 2025-08-01 美商奧迪希治療公司 抗cdh17抗原結合蛋白及其用途
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025114529A1 (en) 2023-12-01 2025-06-05 Ablynx Nv Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
US6742038B2 (en) 2000-04-07 2004-05-25 Danger, Inc. System and method of linking user identification to a subscriber identification module
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
US9028816B2 (en) 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
US20090191217A1 (en) 2004-12-02 2009-07-30 De Wildt Ruud M Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
US8188223B2 (en) * 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
JP2009519011A (ja) 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
CA2629850A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EA201270174A1 (ru) * 2009-07-16 2012-07-30 Глэксо Груп Лимитед Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
CN102666586A (zh) 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
SG188204A1 (en) * 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
JP2014501515A (ja) * 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
JP6258199B2 (ja) 2011-06-23 2018-01-10 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術
HRP20192160T1 (hr) 2011-06-23 2020-02-21 Ablynx N.V. Vezujući proteini serumskog albumina
IN2014CN00437A (enExample) * 2011-06-23 2015-04-03 Ablynx Nv
WO2012174741A1 (en) 2011-06-24 2012-12-27 Google Inc. Determining cross-language query suggestion based on query translations
UA118833C2 (uk) 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2014037419A1 (en) 2012-09-04 2014-03-13 Vib Vzw Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en) 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
SI3248986T1 (sl) 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
LT3611192T (lt) * 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
KR20180080337A (ko) 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
CN110191896B (zh) 2017-01-17 2023-09-29 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
KR102653724B1 (ko) * 2017-01-17 2024-04-02 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538566A (ja) 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体

Also Published As

Publication number Publication date
JP2025131869A (ja) 2025-09-09
MX2023007520A (es) 2023-07-06
US11414480B2 (en) 2022-08-16
IL266907A (en) 2019-07-31
RU2019120720A3 (enExample) 2021-02-25
JP7417421B2 (ja) 2024-01-18
CN110049997B (zh) 2023-09-22
AU2017373746A1 (en) 2019-05-30
US20190367596A1 (en) 2019-12-05
MX2019006574A (es) 2019-08-21
BR112019011189A2 (pt) 2019-10-08
EP3551656A1 (en) 2019-10-16
KR20190091524A (ko) 2019-08-06
CN117164710A (zh) 2023-12-05
KR20240001271A (ko) 2024-01-03
CA3045726A1 (en) 2018-06-14
US20230050615A1 (en) 2023-02-16
RU2022101604A (ru) 2022-03-29
RU2019120720A (ru) 2021-01-12
WO2018104444A1 (en) 2018-06-14
IL266907B1 (en) 2024-03-01
MX2023003630A (es) 2023-04-11
CN110049997A (zh) 2019-07-23
IL266907B2 (en) 2024-07-01
JP2023109939A (ja) 2023-08-08
KR20230061582A (ko) 2023-05-08
RU2765384C2 (ru) 2022-01-28
AU2025200245A1 (en) 2025-01-30
AU2017373746B2 (en) 2024-11-14
JP2020511113A (ja) 2020-04-16
IL310340A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
KR102616835B1 (ko) 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
US20230060574A1 (en) Serum albumin binders
US20240294617A1 (en) Serum albumin binders
HK40018516A (en) Improved serum albumin binders
HK40018516B (en) Improved serum albumin binders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190705

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201007

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221030

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230427

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230915

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231218

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231218

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231218

End annual number: 3

Start annual number: 1

PG1601 Publication of registration